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In this study, purified peptides from shrimp waste hydrolysates (SWHs) were examined for their inhibitory effects
against β–secretase. During consecutive purification using a Sephadex G–25 column chromatography and high
performance liquid chromatography on a C18 column, a potent β–secretase inhibitory peptide Asp–Val–Leu–Phe–
His (629 Da) was isolated and identified from SWH24 by Q–TOF MS/MS and the IC50 value was determined to be
92.70 μM. The β–secretase inhibition patterns of the purified peptides were found to be competitive. Among
synthesized β–secretase inhibitory peptides, Leu–Phe–His had higher β–secretase inhibitory activity than the others.
The result of this study suggests that the β–secretase inhibitory peptide derived from SWH24 could be potential
candidates to develop nutraceuticals and pharmaceuticals.
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Successful public health policies and socioeconomic develop-
ment have resulted in increasing number of elderly population
globally, which are accompanied by challenges to address vari-
ous health issues of an aging society. The World Health
Organization reported in 2012 that 35.6 million people world-
wide are living with dementia or Alzheimer's disease (AD), and
that this number will triple to 115.4 million by 2050 (World
Health Organization and Alzheimer’s Disease International,
2012). Much of AD research has been focused on the amyloid
cascade hypothesis, which states that amyloid beta (Aβ), a pro-
teolytic derivative of the large trans–membrane protein amyl-
oid precursor protein (APP), plays an early and crucial role in
all cases of AD. Consequently, blocking the production of Aβ
by specific inhibition of the β–secretase required for Aβ gener-
ation is a major focus of research into AD therapy (Citron
2004). β–secretase (EC 3.4.23.46), an aspartic peptidase also
known as memapsin 2 and BACE1, is the first protease that
processes APP in the pathway leading to Aβ production. Ex-
cessive levels ofAβ in the brain are closely related toADpatho-
genesis, so much research has been focused on developing* Correspondence: hgbyun@gwnu.ac.kr
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as a therapeutic treatment for AD. High–throughput screen-
ing of compound collections and natural product extracts,
together with drug design building on structure–activity rela-
tionships, have led to the discovery and development of both
peptide and non–peptide inhibitors of the enzyme. These in-
clude compounds such as the peptidic β–secretase inhibitor
OM99–1, other aspartic protease inhibitors, an eight–residue
transition state inhibitor OM99–2 (Chen et al. 1995), and a
more potent eight–residue transition state inhibitor OM00–3
(Turner et al. 2001). Chitosan derivatives from crab shell ex-
hibited weak β–secretase inhibition (Byun et al. 2005), while
catechins from green tea, ellagic acid from pomegranate
(Kwak et al. 2005), hispidin frommycelial cultures of Phellinus
linteus (Park et al. 2004), and several compounds isolated from
Sanguisorbae radix (Lee et al. 2011) have also all been studied
as β–secretase inhibitors. Moreover, several hydroxyl–con-
taining inhibitors have been reported (Cumming et al. 2004).
Shrimp have a high market value but the remaining
heads and shells, which account for half of the shrimp
weight, are typically removed after processing (Cheung
et al. 2012). Many studies have examined the potential
use of these underutilized materials, termed shrimp
processing by–products, for functional properties that are
applicable to industries such as pharmaceutical, functionale is distributed under the terms of the Creative Commons Attribution 4.0
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Li–Chan 2010).
Functional peptides can be produced from enzymatic hy-
drolysis of various bio–resource proteins. Bioactive peptides
are usually 3–10 amino acid residue chains whose activity
is based on their amino acid composition and sequence
(Stachel et al. 2004), and whose functions include regulatory
effects related to nutrient uptake, immune defense (Chen
et al. 1995), and antioxidant activity (Mendis et al. 2005).
Moreover, some peptides can influence higher brain func-
tions, such as learning and memory, in humans and animals
(Mclay et al. 2001). However, there is a paucity of informa-
tion on bioactive peptides from food–derived products,
which may have potential to serve as β–secretase inhibitors.
The objective of this study was to isolate and characterize
β–secretase inhibitory peptides purified from shrimp waste
hydrolysates, and to elucidate the active component pep-
tide(s) and the mode of inhibition of β–secretase.
Methods
Materials
Shrimp processing by–products (including shells, heads
and tails recovered from hand–peeling of cooked shrimp
Pandalopsis dispar) in frozen form were donated by Albion
Fisheries Ltd. (Vancouver, BC, Canada). Shrimp wastes
hydrolysis was performed under experimental conditions
according to Cheung and Li-Chan (2010). Protamex®
(Bacillus amyloliquefaciens and Bacillus licheniformis,
1.5 AU/g), a product from Novozymes North America Inc.
(Salem, NC), was donated by Neova Technologies Inc.
(Abbotsford, BC, Canada). β–secretase and MCA–
EVKMDAEFK–(DNP)–NH2 (β–secretase substrate I)
was purchased from Sigma Chemical Co. (St. Louis,
MO). All other reagents used in this study were reagent
grade chemicals.
Preparation of shrimp waste hydrolysates(SWHs)
SWHs were prepared using Protamex enzyme for hydro-
lysis of the shrimp waste under varying conditions of
water:substrate ratio (1:1, 1:1.5, 1:2 or 1:2.5), percent en-
zyme (2, 4, 6 or 8 % w/w protein contents of shrimp
processing by–products) and time of hydrolysis (1, 4, 8
or 24 h) (Table 1). The lyophilized hydrolysates wereTable 1 The conditions for hydrolysis of shrimp processing by–
products
Sample Hydrolysis conditions
Protease W:S Enzyme(%) Time(h) pH
SWH1 Protamex 1.5:1 4 1 8.4
SWH4 Protamex 2.5:1 6 4 8.3
SWH8 Protamex 2:1 2 8 8.3
SWH24 Protamex 1:1 8 24 8.0stored at −80 °C until use. The SWHs was provided
from Li–Chan’s laboratory in UBC, Canada.Measurement of β–secretase inhibitory activity
β–Secretase inhibitory activity was measured following
Johnston et al. (2008), using a commercially available
fluorogenic substrate, MCA–EVKMDAEFK–(DNP)–
NH2. This substrate corresponded to the wild–type
APP sequence, derivatised at its N–terminus with a
fluorescent 7–methoxycoumarin–4–yl acetyl (MCA)
group, and on its C–terminal lysine residue with a
2,4–dinitrophenyl (DNP) group. In the intact peptide
the fluorescence of the MCA group was abolished by
internal quenching from the DNP group. Upon cleav-
age by β–secretase activity the MCA fluorescence could
be detected. Assays were performed in 96–well black
plates using a Spectrofluorometer (Molecular Devices).
β–secretase and β–secretase substrate I were incubated
in a final volume of 200 μl in assay buffer (50 mM
sodium acetate, pH 4.5). The hydrolysis of β–secretase
substrate I was followed at 37 °C for 30 min, by
measuring the accompanying increase in fluorescence.
Readings (excitation 325 nm, emission 393 nm) were
taken every 60s. The inhibition ratio was obtained by
the following equation: Inhibition (%) = [1– {(S–S0)/
(C–C0)} × 100], where C is the fluorescence of a con-
trol (enzyme, assay buffer, and substrate) after 60 min
of incubation, C0 is the fluorescence of control at zero
time, S is the fluorescence of tested samples (enzyme,
sample solution, and substrate) after 60 min of incuba-
tion, and S0 is the fluorescence of the tested sample at
zero time. All data are the means of triplicate
experiments.Purification of β–secretase inhibitory peptide
The potent fraction as determined from β–secretase
inhibitory activity assay was further purified by size
exclusion chromatography on a Sephadex G–25 gel
filtration column (25 × 750 mm) equilibrated with dis-
tilled water. Separated fractions were monitored at
215 nm, collected at a volume of 7.5 ml and mea-
sured for β–secretase inhibitory activity. The most ac-
tive fraction was then injected into a preparative
reversed phase HPLC column (YMC, ODS C18, 10.0 ×
250 mm, 5 μm) and separated using a linear gradient of
acetonitrile (0–40 % v/v) containing 0.1 % trifluoroace-
tic acid (TFA) on an HPLC system (Agilent Technolo-
gies, USA). The peak showing potent inhibitory activity
was finally purified into a single peptide on a reversed
phase HPLC analytical C18 column (4.6 × 250 mm,
5 μm) using a linear gradient of acetonitrile (0–20 % v/
v) in 0.1 % TFA.
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To identify molecular weight and amino acid sequence
of the purified peptide, all MS/MS experiments were
performed on a Q–TOF tandem mass spectrometer
(Micromass Co., Manchester, UK) equipped with a
nano–ESI source. The peptide solution was desalted
using Capcell Pak C18 UG120 V (4.6 × 250 mm,
5 μm, Shiseido, Tokyo, Japan). The purified peptide dis-
solved in methanol/water (1:1, v/v) was infused into the
ESI source and molecular weight was determined by
doubly charged (M + 2H)2+ state in the mass spectrum.
Following molecular weight determination, peptide was
automatically selected for fragmentation and sequence
information was obtained by tandem MS analysis.Determination of β–secretase inhibition pattern
For the Lineweaver-burk plot, the data were plotted as
mean values of 1/v, the inverse of the increase in fluores-
cence intensity per min (min/DRFU) of three independent
tests with different concentrations of fluorescent substrate.
The assay was performed in the presence of purified
peptide (final concentration of 0, 25, 50 and 100 μg/ml).Synthesis of β‑secretase inhibitory peptides
The peptides were chemically synthesized in the peptide
synthesis facility, PepTron Inc. (Daejeon, Korea). The
peptides were synthesized using the Fmoc–solid phase
method with a peptide synthesizer (PeptrEX–R48, Peptron
Inc., Daejeon, Korea). These synthetic peptides were
purified by RP–HPLC using a Capcell Pak C18 column
(Shiseido, Japan). Elution was performed with a water–
acetonitrile linear gradient (0–80 % of acetonitrile) contain-
ing 0.1 % (v/v) TFA. Elution was monitored at 220 nm on
HPLC instrument (Prominence HPLC, Shimadzu, Tokyo,
Japan).Time (s)































Fig. 1 Effect of shrimp waste hydrolysates (SWHs) on the inhibitory activity of β
substrate I was incubated with hydrolysates (0.5 mg/ml) or buffer (control). b IC
averages (ANOVA, Duncan’s test)Statistical analysis
Each experiment was performed at least three times and
results were presented as the mean ± SD. Statistical com-
parisons of the mean values were performed by analysis
of one–way ANOVA (SPSS 12, IBM, IL, Chicago, USA),
followed by Duncan’s multiple–range test using SPSS
(12) software. Differences were considered significant at
p < 0.05.Results and discussions
β–secretase inhibitory activity of SWHs
β–secretase inhibitory activity was measured using an
assay that we developed and validated using a commer-
cially available fluorogenic substrate. Figure 1a shows
the kinetics of β–secretase inhibitory activity from
SWHs and a control. A fluorescent signal (in relative
fluorescence units) was found over 0–60 min with hy-
drolysates (or buffer) at 0.5 mg/ml and 10 mM β–secre-
tase substrate I. The fluorescence of β–secretase
incubated in the absence of membrane protein was sub-
tracted at each time point. There appeared to be a linear
increase in signal beginning after 5 min that continued
for up to 1 h. Among hydrolysates, SWH24 was particu-
larly potent. As seen in Fig. 1b, the lowest IC50 value
was exhibited by SWH24 at 0.54 mg/ml. These discrep-
ancies may be attributed to differences in substrate spe-
cificity and conditions for optimal activity of the enzyme
preparations, as well as to differing peptide sequences
and structural factors affecting reactivity of the protein
substrates. The findings underline the importance of
selecting the appropriate combination of experimental
conditions to release bioactive peptide sequences
(Cheung and Li–chan 2010). Protamex hydrolysates has
previously been reported to be effective in various bio-
activity such as producing potent ACE inhibitory pep-
tides from marine source (He et al. 2007).Sample






















–secretase. a Relative fluorescence unit of SWHs under 10 mM β–secretase
50 value (mg/ml) of SWHs. Letters indicate significantly (P< 0.05) different
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The use of Sephadex G–25 chromatography led to a
fraction with greatly improved β–secretase inhibitory ac-
tivity (Fig. 2–I). First, fraction D from SWH24 had the
highest β–secretase inhibitory activity, with an IC50
value of 0.19 mg/ml. The lyophilized fraction D was fur-
ther separated into eight sub–fractions by HPLC on an
ODS column with a linear gradient of acetonitrile (0–
50 %) (Fig. 2–II). Finally, the purified fraction B2 was
found to have the highest β–secretase inhibitory activity
(Fig. 2–III). The active fraction B2 was subjected to re–
chromatography on the HPLC column using a isocratic
elution with 22.5 % acetonitrile for 30 min, at a flow rateFig. 2 Purification steps of β–secretase inhibitory peptide from SWH24 by
Gel filtration chromatogram of hydrolysates prepared with SWH24 (b, lowe
fraction volume of 7.5 ml. The fractions isolated by Sephadex G–25 Gel col
upper panel (a). II,III,IV HPLC chromatogram of potent β–secretase inhibito
performed with linear gradient of acetonitrile at a flow rate of 1.0 ml/min a
monitored at 215 nm (b, lower layer). The fractions showing β–secretase in
layer (a)of 1.0 ml/min (Fig. 2–IV). The IC50 value of this purified
peptide was 58.31 μg/ml. The β-secretase inhibitory ac-
tivity of purified peptide was increased by 10.52-fold
compared to the SWH24 (0.54mg/ml), using the four
step purification procedure.
Identification of β–secretase inhibitory peptide
The amino acid sequence of the purified β–secretase
inhibitory peptide were identified using MS/MS. For
SWH24, the sequence was found to be Asp–Val–Leu–
Phe–His (629 Da) for fraction B2, with an IC50 value of
92.70 μM (Fig. 3). The amino acid sequence of this
peptide is critical in its β–secretase inhibitory activity.Sephadex G–25 column chromatography and HPLC. I Sephadex G–25
r layer). Separation was performed with 1.5 ml/min and collected at a
umn were separated (A ~ D) and β–secretase activity determined as
ry activity of separated fraction from previous step. Separation was
nd Grom–sil 120 ODS–5 ST column (5 μm, 10 × 250 mm). Elution was
hibitory activity were determinded IC50 (mg/ml) as shown in upper
Max. 503.4 cps.


























































Fig. 3 Identification of molecular weight and amino acid sequence of the purified peptide from SWH24 by HPLC. MS/MS experiments were performed
on a Q–TOF tandem mass spectrometer equipped with a nano–ESI source
1/[S]














Fig. 4 Lineweaver–burk plots for determining inhibition pattern of
the purified inhibitor against β–secretase. The intersection of the
three lines on the vertical axis signified that the purified β–secretase
inhibitor was a competitive inhibitor
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inhibitor, KMI–370 (IC50 value = 3.4 nM), whose activity
was greater than that of the purified peptide (IC50 value
= 92.70 μM). Because its molecular weight was much
smaller than those of the others, it was considered suitable
for absorption in the intestine. Lee et al. (2007) found that
the amino acid sequence of a purified β–secretase inhibi-
tor peptide from Saccharomyces cerevisiae was Gly–Pro–
Leu–Gly–Pro–Ile–Gly–Ser with N–terminal sequence
analysis. The molecular weight of the purified β–secretase
inhibitor was estimated to be 697 Da by LC–MS, and its
β–secretase inhibitory activity IC50 value was 2.59 μM. In
spite of having the highest inhibition efficiency, they re-
ported that this octapeptide needs a reduced molecular
weight to overcome metabolic instability. The purified β–
secretase inhibitory peptide acted competitively with a
substrate according to the Lineweaver–burk plots (Fig. 4).
This strongly suggests that the purified peptide might have
an affinity for the active site of an enzyme where the sub-
strate also binds; the substrate and inhibitor compete for
access to the enzyme's active site. Derivatives of these pep-
tides are expected to be useful in the prevention of AD
through the development of novel peptidic inhibitors.
Availability of protein/ligand structures has opened up the
possibility of structure–based design of β–secretase inhib-
itors. Prototypical aspartic acid protease inhibitors are
peptides of high molecular weight, and contain a sec-
ondary alcohol that acts as a transition-state mimetic
via the formation of hydrogen bonds with the catalyticaspartic acid groups (Bursavich and Rich 2002). Potent
transition state–mimetic β–secretase inhibitors have
been reported by several groups, and the area has been
reviewed recently (Hong et al. 2005). OM99–2, a syn-
thesized peptidyl inhibitor of human brain β–secretase
(Hong et al. 2005), was utilized to learn the interactions
of the β–secretase active site. The inhibitor was bound
in the substrate–binding cleft located between the
Li-Chan et al. Fisheries and Aquatic Sciences  (2016) 19:11 Page 6 of 7N– and C–terminal lobes. Six of the eight OM99–2
residues (P4 ~ P'2) are bound in the active site of β–
secretase in an extended structure and their respective
binding sites (S4 ~ S'2) are well–designated by atomic
contacts with the inhibitor side.
β–secretase inhibitory activity of synthetic peptides
The peptide Asp–Val–Leu–Phe–His was purified from
SWH24. Based on it, five synthetic peptides were
prepared in order to study their β–secretase inhibitory
activity relative to their amino acid sequences. They
were further purified using a reversed–phase HPLC.
The resulting IC50 values of the synthetic peptides are
shown in Table 2. Among the synthetic peptides, the
IC50 value of Leu–Phe–His was 34.11 μM. Moreover,
the IC50 values of the synthetic peptides were improved
over the original peptide isolated from SWH24 (Asp–
Val–Leu–Phe–His, IC50, 92.70 μM). Synthesized Leu–
Phe–His acted competitively according to the Linewea-
ver–Burk plot (data not shown). In both peptides (Asp–
Val–Leu–Phe–His and Leu–Phe–His), leucine is likely to
be the important residue for β–secretase inhibition. In the
β–secretase inhibitory mechanism, leucine plays an im-
portant role in the Swedish mutant APP, which has a mu-
tation at the P2–P1 positions from Lys–Met to Asn–Leu.
Generally, β–secretase has eight (P1 ~ P4 and P1' ~ P4')
residues that are important in the catalytic domain, deter-
mined by its crystal structure. Inhibitory activities against
β–secretase when the P2 position was changed to several
other amino acids have been described (Hong et al. 2005).
In the case of hydrophilic amino acids (Asp, Asn, Glu, and
Gln) in the P2 position, the inhibitory activities were weak
(β–secretase inhibitory activity of 25–36 %). However,
with hydrophobic amino acids like leucine in the P2 pos-
ition, significant inhibitory activity was present (β–secre-
tase inhibitory activity of >90 %). These results suggested
that a hydrophobic interaction at the P2 site of β–secre-
tase was more effective than a hydrophilic one, in spite of
the hydrophilic property of the P2 site. Leucine was
employed as the P2 moiety for the synthetic β–secretase
inhibitor. The isolated and synthesized peptides may not
be directly considered as potential drug candidates, since
they have relatively groups. However, this is the firstTable 2 β–secretase inhibitory activity of synthesized peptides
Synthesized Peptide IC50 value (μM)
Asp–Val–Leu–Phe–His 101.54 ± 11.54a
Asp–Val–Leu 41.93 ± 4.14c
Asp–Val 67.46 ± 7.83b
Leu–Phe–His 34.11 ± 9.01c
Phe–His 104.76 ± 8.67a
a-c, Letters indicate significantly (P < 0.05) different averages (ANOVA,
Duncan’s test)report on the β–secretase inhibiting activity of marine or-
ganisms. These isolated and synthesized peptides from
SWH24 could be useful in the study of the mechanisms of
Alzheimer’s disease.
Conclusion
In conclusion, the hydrolysate of shrimp waste protein
generated by proteinases treatment followed by consecu-
tive purification of gel filtration and reversed-phase HPLC
resulted in a novel β-secretase inhibitory peptide of
DVLFH. The purified peptide acted as a competitive in-
hibitor against β-secretase with an IC50 value of 92.70 μM
and molecular weight of 629 Da. We were synthesized
novel β-secretase inhibitory peptide base on amino acid
sequences of DVLFH. Among the synthesized peptides,
LFH had higher β–secretase inhibitory activity the other
synthesized peptides. Our present results proposed that
the β–secretase inhibitory peptides derived shrimp waste
protein could be used as nutraceutical ingredients and alz-
heimer’s disease medicine. The manufacturing of hydroly-
sates and peptides loaded with bioactive peptide-rich
protein from shrimp by–products could be a new possibil-
ity for functional foods.
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